Understanding how clear cell cancers respond to immunotherapy
Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers
['FUNDING_U01'] · STANFORD UNIVERSITY · NIH-10918272
This study is looking at how clear cell ovarian cancer responds to immunotherapy, with the goal of figuring out which patients might benefit the most from these treatments.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10918272 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind how clear cell cancers, particularly clear cell ovarian cancer (ccOC), respond to immunotherapy. By analyzing the tumor microenvironment and the spatial organization of different cell types, the study aims to identify which patients are most likely to benefit from immune checkpoint inhibitors. The research employs systems biology approaches to compare the cellular composition and behavior of clear cell cancers, enhancing our understanding of their unique characteristics. Ultimately, this work seeks to improve patient selection for immunotherapy treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell ovarian cancer or other clear cell cancers who are considering immunotherapy.
Not a fit: Patients with non-clear cell cancers or those who do not have a diagnosis of clear cell cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with clear cell cancers.
How similar studies have performed: Other research has shown promising results in understanding immune responses in similar cancer types, suggesting potential for success in this area.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GENTLES, ANDREW J. — STANFORD UNIVERSITY
- Study coordinator: GENTLES, ANDREW J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.